This edition of the Carnival of Biotechnology features some interesting commentary on issues ethics, how to dress for drug ads, progress in biogenerics guidance, and innovation.
Signals Magazine presents a Financial Snapshot For September 2006
The Pharma Marketing Blog gives us some fashion advice in Lipitor’s Jarvik: Fop or Flop?
The Patent Baristas give us a double-header: Are Conflicts of Interest on The Rise? and Should Doctors Be Paid To Give Inside Info To Wall Street?
Signals Magazine presents an update on the Bio-Generic Regulatory Debate and matching commentary in Gearing Up For Bio-Generics
On Pharma asks Are Pharma’s Lean Projects Having an Impact?
This edition of the Carnival of Biotechnology features commentary on regulatory problems and progress, international development, and failed commercialization strategies.
The Washington Post has a report from the Institute of Medicine claiming that the drug review system is broken, and calling for changes.
The Patent Barista’s update the road to biogenerics, profiling recent bills aimed at formalizing processes to approve generic versions of biologic drugs.
Pharmalicensing has a post on the costs and benefits of clinical trials in India.
Solata Advisors have a brief post on the evils of starting from technology – it is preferable to start a company by seeking to serve a market rather than develop a technology for which no market may exist.
Welcome to this week’s edition of the Carnival of Biotechnology. Some pretty good stuff this week. More Vioxx news, the human genome stops by for an update, and no love for the FDA.
SignalsMag provides an update on March financials: Modest Gains, Solid Quarter.
The Drug Wonks take a Dumb and Dumber approach to drug price controls, an excellent case of argumentum ad absurdum.
Following the the same vein, Pharma Marketing explains how the New England Journal of Medicine was Hoodwinked by Merck.
In another post, Pharma Marketing explains why the FDA’s grade just went from pass to fail.
The human genome is back in the news, this time reporting for what hopefully will be the last time, that the entire sequence of the human genome has finally been completed.
The Times has an article on Frankencotton where they introduce genetically modified shirts and ask why nobody seems to be afriad of genetically modified clothes.
This week’s edition of the Carnival of Biotechnology addresses a number of issues challenging the biotechnology industry today.
About biotech proclaims Innovation is dead, long live innovation! in the wake of Proctor & Gamble’s spin of the dissolution of it’s pharma R&D efforts as a bold new innovation strategy.
A Vc asks changing our expectations and creating a second way for drugs to come to market can solve the ills facing the industry.
The Drug Wonks present their modest proposal, a solution for those concerned about big pharma’s unreasonable drug prices
With a number of medical blunders such as the withdrawal of Vioxx, disastrous clinical trials, and now Bausch & Lomb’s association with fungal infections, Eye on FDA presents guidelines to avoiding a crisis in communications during a medical product crisis.
Feeling unloved? Money magazine has rated biotechnology research scientists as the 35th-best job in America. Enjoy the ride while it lasts – these jobs aren’t immune to offshoring.
That’s it for this edition of the Carnival of Biotechnology. Don’t forget to submit your items, and if you’re interested in hosting the carnival, drop a line to firstname.lastname@example.org
The latest carnival of biotechnology has been posted at Patent Baristas. Check it out for a fresh outlook on issues driving the industry today.
Welcome to this edition of the Carnival of Biotechnology. The next edition will be hosted at Patent Baristas. If you’re interested in hosting the Carnival, drop an email to email@example.com.
While not technically a blog post, this article from CNN highlights an oft-ignored element of biotechnology, supplying laboratories. Raising lab animals is big business.
About Biotech has a roundup of 2005 retrospectives and future projections for the biotechnology industry.
Signalsmag profiles merger and acquisition activity in 2005 and finds that M&A’s were hot in 2005.
John Mack at Pharma Marketing tells us about a new trend in pharma, detailing generic drugs.
The Patent Baristas shed light on an exciting new development the European Medicines Agency (EMEA) has set guidelines on biosimilar drugs.
Hope you enjoyed this edition of the carnival. Check out next week’s host, Patent Baristas, and submit your items.
Welcome to the inaugural Carnival of Biotechnology. This roundup of the best blogs on biotechnology brings together the best posts covering the industry.
This week’s carnival is hosted here at Biotechblog.com. The next post will be at About.com Biotechnology.
For more information about the Carnival of Biotechnology, see the Carnival’s homepage.
Without further ado, here’s this week’s entry:
Finance and business development
Ben McClure at at Investopedia has put together a sample case of Using DCF In Biotech Valuation. This excellent tutorial provides a clear example of how to apply this commonly used biotech valuation tool.
The Drugwonks aren’t bashful in their critique of price controls. In ‘Of Barn Doors and Horses‘ they bemoan the inefficient circle of impeding vaccine development through price controls, tort liabilities and other factors while providing government incentives to foster the development of vaccines.
In a trifecta of posts directed at reimportation, the Drugwonks explain that Counterfeit Drugs are a Global Problem, imported drugs shouldn’t be used Because They’re Illegal and Unsafe and ask Who’s Next, given the dramatic increase in counterfeit drugs seizures over the past decade.
See you next time at About.com Biotechnology.
The Carnival of Biotechnology is a regular roundup of the best blog posts on biotechnology. The carnival is guest-hosted by different sites, ensuring diversity in content and viewpoints. Check out the info page and submit your article or sign up to host the carnival.
After much frustration with the previous blog host for BiotechBlog, we’ve now moved to a new home at WordPress. Initial reactions are quite positive. Hope you like the new design.
This blog post and the ensuing discussion present an interesting and revealing dialogue on the practicality of creating an open marketplace for biotech patents; the benefits of open-licensing must be weighed against the high capital and time requirements for vetting and development.